Avantor, Inc. is a life science tools company that engages in providing mission-critical products and services to the life sciences and advanced technology industries. The company is headquartered in Radnor, Pennsylvania and currently employs 13,500 full-time employees. The company went IPO on 2019-05-17. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
How did AVTR's recent EPS compare to expectations?
The most recent EPS for Avantor Inc is $0.17, beating expectations of $0.16.
How did Avantor Inc AVTR's revenue perform in the last quarter?
Avantor Inc revenue for the last quarter is $0.17
What is the revenue estimate for Avantor Inc?
According to 17 of Wall street analyst, the revenue estimate of Avantor Inc range from $1.73B to $1.56B
What's the earning quality score for Avantor Inc?
Avantor Inc has a earning quality score of B/43.539703. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Avantor Inc report earnings?
Avantor Inc next earnings report is expected in 2026-07-28
What are Avantor Inc's expected earnings?
Avantor Inc expected earnings is $1.57B, according to wall-street analysts.
Did Avantor Inc beat earnings expectations?
Avantor Inc recent earnings of $1.58B beat expectations.